Investigation Overview
An investigation on behalf of investors, who currently hold shares of Dimension Therapeutics Inc (NASDAQ:DMTX), was announced concerning whether the takeover of Dimension Therapeutics Inc by REGENXBIO Inc for a value of approximately $3.41 per share is unfair to NASDAQ:DMTX stockholders. The investigation by a law firm concerns whether certain officers and directors of Dimension Ther...
You must register (for free) or login to view the entire investigation.